Showing 1,261 - 1,280 results of 60,812 for search '(( 50 ((ms decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (nn decrease)) ))', query time: 1.04s Refine Results
  1. 1261

    Decreased Platelet Count in Patients Receiving Continuous Veno-Venous Hemofiltration: A Single-Center Retrospective Study by Buyun Wu (563610)

    Published 2014
    “…<div><p>Background</p><p>A decreased platelet count may occur and portend a worse outcome in patients receiving continuous renal replacement therapy (CRRT). …”
  2. 1262

    Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

    Published 2018
    “…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC<sub>50</sub> value in micromolar range. …”
  3. 1263

    Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

    Published 2018
    “…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC<sub>50</sub> value in micromolar range. …”
  4. 1264
  5. 1265

    Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. by David Herrero Martín (286820)

    Published 2013
    “…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC<sub>50</sub> concentration of fenretinide during different time points (24–48–72 hours). …”
  6. 1266
  7. 1267

    Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells. by Mariam El-Ashmawy (678638)

    Published 2014
    “…(A) HBEC 3KT, (B) HME1, and (C) PBMCs were treated with CDDO-Me 18 hours prior to IR, then mounted on slides 30 min post-IR. …”
  8. 1268
  9. 1269

    Table_1_What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral lo... by Fabian Aldunate (3935021)

    Published 2023
    “…In addition, we found evidence of an increase in antibody titers after transfusion, accompanied by a decrease in the levels of several cytokines responsible for cytokine storm.…”
  10. 1270

    Image_1_What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral lo... by Fabian Aldunate (3935021)

    Published 2023
    “…In addition, we found evidence of an increase in antibody titers after transfusion, accompanied by a decrease in the levels of several cytokines responsible for cytokine storm.…”
  11. 1271
  12. 1272
  13. 1273

    Sequence parameters. by Tobit Führes (12647099)

    Published 2023
    “…Seven healthy volunteers underwent diffusion-weighted magnetic resonance imaging (DWI) with five diffusion encoding schemes (monopolar, velocity-compensated (<i>M</i><sub>1</sub> = 0), acceleration-compensated (<i>M</i><sub>1</sub> = <i>M</i><sub>2</sub> = 0), 84%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated, 67%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated) at b-values of 50 and 800 s/mm<sup>2</sup> at a constant echo time of 70 ms. …”
  14. 1274

    ADC maps of one volunteer. by Tobit Führes (12647099)

    Published 2023
    “…Seven healthy volunteers underwent diffusion-weighted magnetic resonance imaging (DWI) with five diffusion encoding schemes (monopolar, velocity-compensated (<i>M</i><sub>1</sub> = 0), acceleration-compensated (<i>M</i><sub>1</sub> = <i>M</i><sub>2</sub> = 0), 84%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated, 67%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated) at b-values of 50 and 800 s/mm<sup>2</sup> at a constant echo time of 70 ms. …”
  15. 1275

    Absolute values of <i>M</i><sub>1</sub> and <i>M</i><sub>2</sub>. by Tobit Führes (12647099)

    Published 2023
    “…Seven healthy volunteers underwent diffusion-weighted magnetic resonance imaging (DWI) with five diffusion encoding schemes (monopolar, velocity-compensated (<i>M</i><sub>1</sub> = 0), acceleration-compensated (<i>M</i><sub>1</sub> = <i>M</i><sub>2</sub> = 0), 84%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated, 67%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated) at b-values of 50 and 800 s/mm<sup>2</sup> at a constant echo time of 70 ms. …”
  16. 1276
  17. 1277

    Structure–Activity Studies of 1<i>H</i>‑Imidazo[4,5‑<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators by Lucas B. Fallot (14106171)

    Published 2022
    “…We previously reported 1<i>H</i>-imidazo[4,5-<i>c</i>]quinolin-4-amines as A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) positive allosteric modulators (PAMs). …”
  18. 1278

    Structure–Activity Studies of 1<i>H</i>‑Imidazo[4,5‑<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators by Lucas B. Fallot (14106171)

    Published 2022
    “…We previously reported 1<i>H</i>-imidazo[4,5-<i>c</i>]quinolin-4-amines as A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) positive allosteric modulators (PAMs). …”
  19. 1279
  20. 1280